Publication

Article

CURE

Winter 2013
Volume12
Issue 4

Reel Recovery Retreats

Author(s):

Jon Garinn

Reel Recovery offers free fly-fishing retreats for men recovering from cancer.

For men who have cancer, talking about their disease can sometimes be a challenge. That’s why Reel Recovery offers free fly-fishing retreats for men recovering from all forms of cancer. For more than a decade, the nonprofit organization has combined expert fly-fishing instruction with directed conversations, giving participants time to share their stories, learn a new skill and form friendships. To learn more about the 2014 retreat lineup, visit reelrecovery.org.

Articles in this issue
Changing Course in Pancreatic Cancer
Message From the Editor
Dose of Reality Effective at Stopping Smokers
Michael Douglas Reveals He Had Tongue Cancer
Studies Confirm Effectiveness of Colorectal Cancer Screening
Reel Recovery Retreats
Dispatch: Society for Integrative Oncology's 10th Annual Meeting
Poor Kidney Function a Possibility in Adult Survivors of Childhood Cancer
Personalized Medicine Should Include High-Quality, High-Value Care
How I Lost My Uterus and Found My Voice
Why Observing Treatment Milestones is an Individual Decision
For Caregivers: Tips Before Planning that "End of Treatment" Party
Solving the Treatment Resistance Riddle
Advances in Screening & Early Detection of Pancreatic Cancer
Post-Mastectomy Pain Hits a Nerve

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!
Related Videos
Image of man with text.
Image of Dr. with text.
Image of thumbnail.
Image of Dr. Deville.
Image of Doctor.
Image of Dr. Tagawa.
Dr. Curtiland Deville Jr. discusses the importance of crafting an individualized treatment plan for patients with prostate cancer.
Use of NeuroSAFE to guide nerve sparing during robot-assisted radical prostatectomy improved patient-reported erectile function.
Dr. Chandler Park, a medical oncologist of Genitourinary Medical Oncology, at the Norton Healthcare Institute, in Louisville, Kentucky.
Dr. Guru Sonpavde emphasized the importance of better understanding how genetic mutations influence the treatment of cancer care, particularly GU cancers.
Related Content
Image of prostate
July 31st 2025

July Prostate Cancer Highlights: Top 5 Updates Patients Should Know

Ryan Scott
New insights highlight how prostate cancer is now managed as a chronic disease, with emerging treatments and real-world data offering renewed hope for patients.
Image of CURE's Cancer Horizons podcast logo: a white microphone with yellow noise lines. Highlights from the 2024 ASCO gastrointestinal and genitourinary cancer conferences.
July 31st 2025

Highlights from the Gastrointestinal and Genitourinary Cancer Conferences

Alex Biese Brielle Benyon
Here are some of the top stories from the recent Gastrointestinal Cancers Symposium as well as the Genitourinary Cancers Symposium.
Dr. Lorenzo Cohen and Alison Jefferies discuss small yet meaningful changes that patients can make to their home environment to foster a sense of wellness: © stock.adobe.com.
July 31st 2025

Meaningful Changes to Reduce Environmental Toxicities

Ryan Scott
Dr. Lorenzo Cohen and Alison Jefferies discuss small yet meaningful changes that patients can make to their home environment to foster a sense of wellness.
CURE Cancer Horizons podcast logo
July 31st 2025

Prostate Cancer Headlines, CAR-T Warnings and Laughter Therapy

Alex Biese Brielle Benyon
CURE® editors discuss last week’s biggest cancer headlines, from Dexter Scott King’s death to the potential of laughter therapy to boost quality of life.
The FDA granted FTD to TRE-515 & radioligand therapy for PSMA+ mCRPC: © stock.adobe.com.
July 31st 2025

Fast Track Status Granted by FDA to TRE-515 in Prostate Cancer

Spencer Feldman
The FDA granted fast track designation to TRE-515 plus radioligand therapy for treating PSMA-positive metastatic castration-resistant prostate cancer.
Image of prostate
July 31st 2025

Long-Term Outcomes Support NCCN Guidelines for Prostate Cancer

Ryan Scott
Patients with nonmetastatic prostate cancer treated according to NCCN Guidelines are more likely to die of other natural causes than from their cancer.